NCT00410774终止1 期
A Phase I/II Study of Fixed-Dose Rate Gemcitabine and Bevacizumab for Postoperative Adjuvant Treatment of Patients With Resected Pancreatic Cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Safety of gemcitabine when administered with bevacizumab as assessed by NCI CTCAE v3.0
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of pancreatic cancer by blocking blood flow to the tumor. Giving gemcitabine and bevacizumab after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This phase I/II trial is studying the side effects of gemcitabine and bevacizumab and to see how well they work in treating patients with pancreatic cancer that has been completely removed by surgery.
详细描述
OBJECTIVES:
Primary
- Determine the safety of adjuvant, fixed-dose rate gemcitabine hydrochloride and bevacizumab in patients with completely resected pancreatic cancer.
- Determine the 1-year disease-free survival rate in patients treated with this regimen.
Secondary
- Determine the 1- and 2-year overall survival rates in these patients.
- Determine the median disease-free survival rate in these patients.
- Determine the median overall survival rate in these patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically or cytologically confirmed adenocarcinoma of the pancreas
- •Completely resected disease
- •Underwent 1 of the following procedures 3-8 weeks ago:
- •Standard pancreaticoduodenectomy (for tumors of the pancreatic head)
- •Distal pancreatectomy (for tumors of the pancreatic tail)
- •No grossly positive surgical margins
- •Positive microscopic margins allowed
- •Nonmeasurable disease
- •No known CNS disease
- •PATIENT CHARACTERISTICS:
- •ECOG performance status 0-1
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception during and for 6 months after completion of study therapy
- •CA 19-9 ≤ 2.5 times upper limit of normal (ULN)
- •Absolute neutrophil count ≥ 1,500/mm³
- •Hemoglobin ≥ 9 g/dL (transfusion or epoetin alfa allowed)
- •Platelet count ≥ 100,000/mm³
- •INR ≤ 1.5 (except in patients receiving full-dose warfarin)
- •Bilirubin ≤ 2.0 mg/dL
- •AST and ALT ≤ 2.5 times ULN
- •Creatinine ≤ 2.0 mg/dL
- •No clinically significant impairment of renal function
- •No postoperative complications, including any of the following:
- •Wound dehiscence or infection
- •Intra-abdominal abscess
- •Pancreatic or biliary leak or fistula
- •Grade 3 or 4 delayed hemorrhage (occurring > 5 days postoperatively)
- •Bowel perforation
- •No abdominal fistula, gastrointestinal perforation, or intra-abdominal abcess within the past 6 months
- •No history of major psychiatric disorder or other chronic medical illness that, in the opinion of the treating physician, contraindicates use of the study drugs or renders the patient at high risk of treatment-related complications
- •No other cancer within the past 5 years except basal cell or squamous cell skin cancer
- •No history of serious systemic disease, including any of the following:
- •Myocardial infarction or unstable angina within the past 12 months
- •New York Heart Association class II-IV congestive heart failure
- •Unstable symptomatic arrhythmia requiring medication
- •Chronic atrial arrhythmia (i.e., atrial fibrillation or paroxysmal supraventricular tachycardia) allowed
- •No history of stroke or transient ischemic attack
- •No symptomatic peripheral vascular disease
- •No significant vascular disease (e.g., aortic aneurysm, aortic dissection)
- •No inadequately controlled hypertension (i.e., blood pressure > 150/100 mm Hg on antihypertensive medication)
- •No prior hypertensive crisis or hypertensive encephalopathy
- •No proteinuria (defined as urine protein:creatinine ratio ≥ 1.0 OR proteinuria ≥ 2+ by dipstick urinalysis OR protein > 1 g by 24-hour urine collection)
- •No serious, nonhealing wound or ulcer
- •No evidence of bleeding diathesis or coagulopathy
- •No significant traumatic injury within the past 28 days
- •PRIOR CONCURRENT THERAPY:
- •See Disease Characteristics
- •No prior chemotherapy or radiotherapy for pancreatic cancer
- 另有 6 项未显示
排除标准
- 未提供
结局指标
主要结局
Safety of gemcitabine when administered with bevacizumab as assessed by NCI CTCAE v3.0
Disease-free survival rate at 1 year
次要结局
- Overall survival rate at 1 and 2 years
- Median disease-free survival rate at 1 and 2 years
- Median overall survival rate at 1 and 2 years
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLCLung CancerNCT00283244UNC Lineberger Comprehensive Cancer Center147
已完成
2 期
Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic CancerPancreatic CancerNCT00460174Northwestern University31
终止
1 期
Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary SyndromeLymphomaNCT00369629Northwestern University14
已完成
2 期
Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic CancerPancreatic CancerNCT00810719University of California, Davis30
终止
2 期
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast CancerBreast CancerNCT00323063Rutgers, The State University of New Jersey49